Clinical trial · Interventional
Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance
MR Imaging to Stratify Prostate Cancer Progression Risk in Patients on Active Surveillance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PI decided to terminate study.
Summary
Brief summary (as posted)
RATIONALE: Sometimes prostate cancer may not need treatment until it progresses. In this case, active surveillance may be sufficient. Diagnostic procedures, such as magnetic resonance imaging, may be a less invasive method of finding prostate cancer that has progressed. PURPOSE: This clinical trial is studying how well magnetic resonance imaging works in detecting cancer progression in patients with early-stage prostate cancer who are undergoing active surveillance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| active surveillance | Other | — | UNRESOLVED |
| biopsy | Procedure | — | UNRESOLVED |
| dynamic contrast-enhanced magnetic resonance imaging | Procedure | — | UNRESOLVED |
| imaging biomarker analysis | Other | — | UNRESOLVED |
| magnetic resonance imaging | Procedure | — | UNRESOLVED |
| magnetic resonance spectroscopic imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Prostate cancer progression measured by MRI while on active surveillance
- timeFrame
- at 6 months, 1 year and than annualy for 5 years
Secondary outcomes (1)
- measure
- Prostate cancer changes by MRI
- timeFrame
- At 6months, 1 year and annually for 5 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed prostate cancer * Low-risk for progression, as evidenced by all of the following: * Tumor stage ≤ T2a * PSA ≤ 10 ng/mL * Gleason score ≤ 7 * Patients informed of treatment options and has already chosen to undergo active surveillance * No decision to stop active surveillance * No node-positive or metastatic disease PATIENT CHARACTERISTICS: * Willing to undergo MRI * Willing to undergo prostate biopsy * No contraindications to MRI that include, but not limited to, any of the following: * Claustrophobia * Anxiety * Presence of metal or shrapnel in the body * Pacemakers * Old tattoos with metal-based dye material * No contraindication to prostate biopsy * No medical conditions, as deemed by the PI or associates, that would prevent or limit the patient participation on the protocol that include, but not limited to, any of the following: * Severe coagulopathy * History of severe bleeding * Severe coronary artery disease * Other comorbid conditions that limit life expectancy to less than 2 years PRIOR CONCURRENT THERAPY: * No hormone therapy within the past year * No prior pelvic radiotherapy * No prior prostate resection including transurethral resection of prostate * Concurrent participation in other clinical studies (e.g., vitamin D, selenium) allowed provided active surveillance is continued
References
Publications (0)
Data not yet available